Medroxyprogesterone
Based on 11 publication(s) in Google Scholar
Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469).
For research use only. We do not sell to patients.
- Purity: 98.82%
- CAS No.: 520-85-4
- Formula: C22H32O3
- Molecular Weight:344.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Lipid Compound Library
HY-L043
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Nuclear Receptor Compound Library
HY-L126
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Drug Fragment Library
HY-L904
Publications Citing Use of MedChemExpress (MCE) Medroxyprogesterone
More- Cancer Cell Int. 2021 Jun 5;21(1):291. [Abstract]
- Chem Biol Interact. 2026 Jul 25:435:112138. [Abstract]
- Commun Biol. 2025 Jul 4;8(1):995. [Abstract]
- Invest Ophthalmol Vis Sci. 2022 Sep 1;63(10):3. [Abstract]
- BMC Biol. 2022 Dec 8;20(1):276. [Abstract]
- FASEB J. 2024 May 15;38(9):e23622. [Abstract]
- Oncotargets Ther. 2020 Nov 13;13:11669-11688. [Abstract]
- J Assist Reprod Genet. 2025 Feb;42(2):665-678. [Abstract]
- Placenta. 2021 Jan 1:103:1-9. [Abstract]
- Patent. US20200129476A1
- Austin J Radiol. 2020 Apr.
Biological Activity
Medroxyprogesterone (10 nM, 48 h) has induced Cyclin D1 expression through the PI3K/Akt signaling pathway to promote cell proliferation in T47D cells [1].
Medroxyprogesterone (100 nM, 24 h) has increased the number of monocytes adhering to HUVECs by increasing the expression of adhesion molecules in HUVEC cells, which may be the cause of atherosclerosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T47D
-
Concentration:10 nM
-
Incubation Time:24 h, 48 h, 72h
-
Result:Increased the number of cells at 48 h.
-
Cell Line:T47D
-
Concentration:10 nM
-
Incubation Time:4 h
-
Result:Induced the expression of Cyclin D1 protein.
-
Cell Line:HUVECs
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Increased mRNA and protein expression of adhesion molecules.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ApoE-/- mice model[3]
-
Dosage:27.7 μg/day
-
Administration:s.c.
-
Result:Reduced atherosclerotic plaque and increased thrombosis.
Chemical Information
-
CAS No. 520-85-4
-
Appearance Solid
-
Molecular Weight 344.49
-
Formula C22H32O3
-
Color White to off-white
-
SMILES
C[C@@]1([C@@]2(O)C(C)=O)[C@](CC2)([H])[C@@](C[C@H](C)C3=CC4=O)([H])[C@]([C@]3(CC4)C)([H])CC1
-
Synonyms
17α-Hydroxy-6α-methylprogesterone; U8840
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell Int
Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]2021 Jun 5;21(1):291. PMID: 34090418 -
Chem Biol Interact
Autophagy attenuates the secondary senescence of endometrial stromal cells induced by Bisphenol S. [Abstract]2026 Jul 25:435:112138. PMID: 42114668 -
Commun Biol
Endometrial stromal Menin supports endometrial receptivity by maintaining homeostasis of WNT signaling pathway through H3K4me3 during WOI. [Abstract]2025 Jul 4;8(1):995. PMID: 40610728 -
Invest Ophthalmol Vis Sci
AKR1C1 Protects Corneal Epithelial Cells Against Oxidative Stress-Mediated Ferroptosis in Dry Eye. [Abstract]2022 Sep 1;63(10):3. PMID: 36066316 -
BMC Biol
An IGF1-expressing endometrial stromal cell population is associated with human decidualization. [Abstract]2022 Dec 8;20(1):276. PMID: 36482461 -
FASEB J
Long noncoding RNA BMPR1B-AS1 stability regulated by IGF2BP2 affects the decidualization in endometriosis patients through the SMAD1/5/9 pathway. [Abstract]2024 May 15;38(9):e23622. PMID: 38703029 -
Oncotargets Ther
Identification and Validation of MSX1 as a Key Candidate for Progestin Resistance in Endometrial Cancer. [Abstract]2020 Nov 13;13:11669-11688. PMID: 33235459 -
J Assist Reprod Genet
FXYD1 was identified as a hub gene in recurrent miscarriage and involved in decidualization via regulating Na/K-ATPase activity. [Abstract]2025 Feb;42(2):665-678. PMID: 39730944 -
Placenta
Role of Slit2 upregulation in recurrent miscarriage through regulation of stromal decidualization. [Abstract]2021 Jan 1:103:1-9. PMID: 33068960 -
-
Solvent & Solubility
DMSO : 50 mg/mL (145.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Saitoh M, et al. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005 Nov;146(11):4917-25. [Content Brief]
[2]. Ito F, et al. Medroxyprogesterone acetate enhances monocyte-endothelial interaction under flow conditions by stimulating the expression of cell adhesion molecules. J Clin Endocrinol Metab. 2014 Jun;99(6):2188-97. [Content Brief]
[3]. Freudenberger T, et al. Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. Br J Pharmacol. 2009 Dec;158(8):1951-60. [Content Brief]
[4]. Yusop SNW, et al. Medroxyprogesterone derivatives from microbial transformation as anti-proliferative agents and acetylcholineterase inhibitors (combined in vitro and in silico approaches). Steroids. 2020 Dec;164:108735. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9028 mL | 14.5142 mL | 29.0284 mL | 72.5710 mL |
| 5 mM | 0.5806 mL | 2.9028 mL | 5.8057 mL | 14.5142 mL | |
| 10 mM | 0.2903 mL | 1.4514 mL | 2.9028 mL | 7.2571 mL | |
| 15 mM | 0.1935 mL | 0.9676 mL | 1.9352 mL | 4.8381 mL | |
| 20 mM | 0.1451 mL | 0.7257 mL | 1.4514 mL | 3.6286 mL | |
| 25 mM | 0.1161 mL | 0.5806 mL | 1.1611 mL | 2.9028 mL | |
| 30 mM | 0.0968 mL | 0.4838 mL | 0.9676 mL | 2.4190 mL | |
| 40 mM | 0.0726 mL | 0.3629 mL | 0.7257 mL | 1.8143 mL | |
| 50 mM | 0.0581 mL | 0.2903 mL | 0.5806 mL | 1.4514 mL | |
| 60 mM | 0.0484 mL | 0.2419 mL | 0.4838 mL | 1.2095 mL | |
| 80 mM | 0.0363 mL | 0.1814 mL | 0.3629 mL | 0.9071 mL | |
| 100 mM | 0.0290 mL | 0.1451 mL | 0.2903 mL | 0.7257 mL |
Medroxyprogesterone Related Classifications
HY-B0648 Related Classifications
Powered by Bioz